Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
TG Therapeutics, Inc.
NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more
NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more
NCT06667687 · Non-Hodgkin's Lymphoma
NCT04664179 · EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, and more
NCT07239323 · B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, and more
TG Therapeutics Investigational Trial Site
Duarte, California
TG Therapeutics Investigational Trial Site
San Diego, California
TG Therapeutics Investigational Trial Site
Sarasota, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions